report_lead_image_with_gradient.png
Q1 2026

PitchBook Analyst Note: The Chinese Biopharma Landscape: Where New Assets Are Born

Download this Report
To download this report, please complete the form below

China biopharma rebounds as early-stage innovation fuels dealmaking

China’s biopharma sector is entering 2026 with renewed momentum, reinforcing its position as a global engine for early-stage drug innovation. After a prolonged downturn, venture activity in the sector stabilized in 2024 and rebounded throughout 2025, setting the stage for a more resilient, self-funded ecosystem in Q1 2026. While non-Chinese VC participation continues to retreat, rising domestic capital and streamlined clinical infrastructure are supporting a new wave of well-capitalized private companies with globally relevant pipelines.

Year-over-year activity highlights a clear shift toward next-generation modalities. Deal flow is accelerating in precision oncology, antibody-drug conjugates, nucleic-acid therapies, and metabolic disease, even as small-molecule funding contracts. Major outlicensing deals—such as multibillion-dollar RNA-focused partnerships with global pharma companies—underscore China’s growing lead in early-stage asset generation, while selective M&A and IPO successes signal a reopening exit environment. Looking ahead, continued licensing, targeted fundraises, and differentiated science suggest China’s biopharma advantage will likely persist despite rising geopolitical friction.


Table of contents
Key takeaways 1
Internal dynamics of China’s biopharma landscape 2
Global engagement with China: Cross-border trends 9
Looking ahead to 2026: Risks, opportunities, and geopolitical trajectories 12
Conclusion: China’s early-stage advantage persists 14